Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
J H Wu, S L Diamond
J H Wu, S L Diamond
Published June 1, 1995
Citation Information: J Clin Invest. 1995;95(6):2483-2490. https://doi.org/10.1172/JCI117949.
View: Text | PDF
Research Article Article has an altmetric score of 5

Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

  • Text
  • PDF
Abstract

Thrombolysis is dramatically slower when high concentrations of lytic agent are used. This paradoxical observation, first described as "plasminogen steal," was originally believed to be due to depletion of extrinsic plasminogen and consequent leaching of clot-bound plasminogen. We report that administration of increasing concentrations of recombinant human tissue plasminogen activator (tPA) to fibrin gels resulted in lysis rates that displayed a maximum, with significantly slower rates found at higher tPA, regardless of whether plasminogen was supplied extrinsically or intrinsically. A similar maximum in lysis rates was observed in a system lacking an extrinsic phase when plasminogen was added to fibrin suspensions preincubated with increasing tPA. Thus, intrinsic plasminogen leakage and alpha 2-antiplasmin were not required for the decreased lysis at high tPA. No maximum was observed for increasing concentrations of urokinase. Using fibrin suspensions or gels preincubated with tPA before addition of plasmin, we report that tPA, but not urokinase, caused a dose-dependent inhibition of the fibronolytic action of plasmin. With respect to optimal dosage schemes and the design of novel lytic agents, these findings indicate that (a) there exists a biochemical mechanism against minimizing reperfusion time with increasing tPA dosages and (b) the fibrin affinity of tPA may cause reduced fibrinolysis by plasmin.

Authors

J H Wu, S L Diamond

×

Total citations by year

Year: 2024 2023 2021 2019 2015 2010 2008 2004 2002 2001 2000 1999 1998 1997 1995 Total
Citations: 2 1 2 2 1 1 1 1 2 1 2 1 3 1 1 22
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (22)

Title and authors Publication Year
Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment
Víteček J, Vítečková Wünschová A, Thalerová S, Gulati S, Kubala L, Capandová M, Hampl A, Robert Mikulík
PloS one 2024
Harnessing micrometer-scale tPA beads for high plasmin generation and accelerated fibrinolysis
Osmond MJ, Dabertrand F, Quillinan N, Su EJ, Lawrence DA, Marr DW, Neeves KB
bioRxiv 2024
Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study
Coupland LA, Rabbolini DJ, Schoenecker JG, Crispin PJ, Miller JJ, Ghent T, Medcalf RL, Aneman AE
Critical Care 2023
Accelerated treatment with rtPA for pulmonary embolism induced circulatory arrest
MJ Bakkum, VL Schouten, YM Smulders, EJ Nossent, MA van Agtmael, PR Tuinman
Thrombosis Research 2021
Breaking the fibrinolytic speed limit with microwheel co-delivery of tissue plasminogen activator and plasminogen.
Disharoon D, Trewyn BG, Herson PS, Marr DWM, Neeves KB
Journal of Thrombosis and Haemostasis 2021
Efficacy of Sonothrombolysis Using Microbubbles Produced by a Catheter-Based Microfluidic Device in a Rat Model of Ischemic Stroke
AJ Dixon, J Li, JM Rickel, AL Klibanov, Z Zuo, JA Hossack
Annals of Biomedical Engineering 2019
Blood clot contraction differentially modulates internal and external fibrinolysis
V Tutwiler, AD Peshkova, GL Minh, S Zaitsev, RI Litvinov, DB Cines, JW Weisel
Journal of Thrombosis and Haemostasis 2019
Targeting Therapeutics Across the Blood Brain Barrier (BBB), Prerequisite Towards Thrombolytic Therapy for Cerebrovascular Disorders—an Overview and Advancements
KK Pulicherla, MK Verma
AAPS PharmSciTech 2015
The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies
C Longstaff, C Thelwell, SC Williams, MM Silva, L Szabó, K Kolev
Blood 2010
Deep Vein Thrombosis of Lower Extremity: Direct Intraclot Injection of Alteplase Once Daily with Systemic Anticoagulation—Results of Pilot Study 1
R Chang, CC Chen, A Kam, E Mao, TH Shawker, MD Horne
Radiology 2008
Pharmacologic Agents in Stroke Prevention, Acute Stroke Therapy, and Interventional Procedures
JJ Connors
Journal of Vascular and Interventional Radiology 2004
Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits
PA Lapchak, DM Araujo, S Pakola, D Song, J Wei, JA Zivin
Stroke; a journal of cerebral circulation 2002
An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator
DM Wootton, AS Popel, BR Alevriadou
Biotechnology and Bioengineering 2002
Thrombosed Hemodialysis Grafts: Lyse and Wait with Tissue Plasminogen Activator or Urokinase Compared to Mechanical Thrombolysis with the Arrow-Trerotola Percutaneous Thrombolytic Device
PM Vogel, V Bansal, MW Marshall
Journal of Vascular and Interventional Radiology 2001
Sequestrated thrombolysis: Comparative evaluation in vivo
S Roy, F Lærum, F Brosstad, K Kvernebo, KS Sakariassen
Cardiovascular and Interventional Radiology 2000
Augmented Experimental Pulse-Spray Thrombolysis with Tissue Plasminogen Activator, Enabling Dose Reduction by One or More Orders of Magnitude
JJ Bookstein, FL Bookstein
Journal of Vascular and Interventional Radiology 2000
Engineering Design of Optimal Strategies for Blood Clot Dissolution
SL Diamond
Annual Review of Biomedical Engineering 1999
Quantitative evaluation of selective thrombolysis techniques: Influence of catheter characteristics and delivery parameters
S Roy, F Lærum, F Brosstad
Catheterization and Cardiovascular Diagnosis 1998
The Kinetics and Affinity of Binding of Glu-Plasminogen Specific to the ϵ-Amino Group ofl-Lysine: Its Potential Application to Modified Biomaterials
PH Warkentin, K Johansen, JL Brash, I Lundström
Journal of Colloid and Interface Science 1998
27. Hämophilie-Symposion Hamburg 1996
I Scharrer, W Schramm
1998
Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics
S Fischer, U Kohnert
Fibrinolysis and Proteolysis 1997
Enzyme-mediated proteolysis of fibrous biopolymers: Dissolution front movement in fibrin or collagen under conditions of diffusive or convective transport
S Anand, JH Wu, SL Diamond
Biotechnology and Bioengineering 1995

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
16 readers on Mendeley
See more details